Potential drug-drug interaction of olverembatinib (HQP1351) using physiologically based pharmacokinetic models

Olverembatinib (HQP1351) is a third-generation BCR-ABL tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia (CML) (including T315I-mutant disease), exhibits drug-drug interaction (DDI) potential through cytochrome P450 (CYP) enzymes CYP3A4, CYP2C9, CYP2C19, CYP1A2, and CYP2B6. A p...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Zhiheng, Lei, Zihan, Yao, Xueting, Wang, Hengbang, Zhang, Miao, Hou, Zhe, Li, Yafen, Zhao, Yangyu, Li, Haiyan, Liu, Dongyang, Zhai, Yifan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792776/
https://www.ncbi.nlm.nih.gov/pubmed/36582520
http://dx.doi.org/10.3389/fphar.2022.1065130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792776/
https://www.ncbi.nlm.nih.gov/pubmed/36582520
http://dx.doi.org/10.3389/fphar.2022.1065130

Ejemplares similares